Jin Matsuyama
Research Subjects
Jin Matsuyama has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Shinsuke Nakashima
The University of Tokyo
5 shared publications - Terumasa Yamada
Department of Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan
5 shared publications - Kiyotsugu Iede
Department of Clinical Oncology, Higashiosaka City Medical Center, Higashiosaka, Japan
4 shared publications Masakazu Ikenaga
Department of Gastroenterological Surgery, Higashiosaka City Medical Center
4 shared publicationsMasami Ueda
Department of Gastroenterological Surgery, Higashiosaka City Medical Center
4 shared publications- Ryohei Kawabata
Department of Gastrointestinal Surgery, Sakai City Medical Center, Sakai, Japan
4 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 53 (1) , 112202
Surgical resection for stage IV gastric cancer: Real-world insights with a focus on elderly patients (OGSG2301)
- 9 October 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 53 (1) , 112202
Open AccessSurgical resection for stage IV gastric cancer: Real-world insights with a focus on elderly patients (OGSG2301)
- Open Access
- 23 September 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 88, 103500
Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial
- 23 September 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 88, 103500
Open AccessEfficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial
- Open Access
- 1 January 2023
- Published by Japanese Society for Surgical Metabolism and Nutrition in The Japanese Journal of SURGICAL METABOLISM and NUTRITION
- Vol. 57 (3) , 81
Effects of an oral elemental nutritional supplement in Gastric Cancer Patients after Gastrectomy.
Introduction:We investigated the effects of an oral elemental nutritional supplement(ELENTALⓇ:ED)on weight loss in the early and long-term postoperative periods and on skeletal muscle mass loss(KSES-001, 002, and 003 studies). Methods:One hundred eleven gastric cancer patients who underwent R0 total gastrectomy(TG)or distal gastrectomy( DG)were randomized into two groups:an ED group of 58 patients who received an elemental nutritional supplement( 300 kcal/day)in addition to usual diet for 6-8 weeks after surgery, and a control group(C group, 53 patients) who received only their usual diet. The weight loss rates were compared 6-8 weeks and one year postoperatively. In addition, lumbar skeletal muscle area at the L3 level preoperatively and 1 year postoperatively was measured using SYNAPSE VINCENT to compare the rate of skeletal muscle loss. Results:The rate of weight loss in the early postoperative period was ED 4.9%/C 6.6%, significantly suppressing the rate of weight loss(P=0.047). There was a significant difference of ED 5.0%/C 9.1% after TG(P=0.012), but no difference after DG. The weight loss rate at 1 year after surgery was ED 7.1%/C 9.1%, with no difference(P=0.171). Although, there was a significant difference of ED 9.7%/C 15.1% after TG(P=0.015). The rate of skeletal muscle loss at 1 year after surgery was ED 8.0%/C 10.1%(P=0.357)overall;after TG;ED 12.5%/C 17.5%(P=0.196)and after DG; ED 5.6%/C 6.2%(P=0.770), all without significant difference. Conclusion:An oral elemental nutritional supplements early after gastrectomy significantly reduced short-term postoperative weight loss, and in TG, also significantly reduced weight loss at 1 year postoperatively. No significant difference in skeletal muscle loss was detected.
- 1 January 2023
- Published by Japanese Society for Surgical Metabolism and Nutrition in The Japanese Journal of SURGICAL METABOLISM and NUTRITION
- Vol. 57 (3) , 81
Open AccessEffects of an oral elemental nutritional supplement in Gastric Cancer Patients after Gastrectomy.
Introduction:We investigated the effects of an oral elemental nutritional supplement(ELENTALⓇ:ED)on weight loss in the early and long-term postoperative periods and on skeletal muscle mass loss(KSES-001, 002, and 003 studies). Methods:One hundred eleven gastric cancer patients who underwent R0 total gastrectomy(TG)or distal gastrectomy( DG)were randomized into two groups:an ED group of 58 patients who received an elemental nutritional supplement( 300 kcal/day)in addition to usual diet for 6-8 weeks after surgery, and a control group(C group, 53 patients) who received only their usual diet. The weight loss rates were compared 6-8 weeks and one year postoperatively. In addition, lumbar skeletal muscle area at the L3 level preoperatively and 1 year postoperatively was measured using SYNAPSE VINCENT to compare the rate of skeletal muscle loss. Results:The rate of weight loss in the early postoperative period was ED 4.9%/C 6.6%, significantly suppressing the rate of weight loss(P=0.047). There was a significant difference of ED 5.0%/C 9.1% after TG(P=0.012), but no difference after DG. The weight loss rate at 1 year after surgery was ED 7.1%/C 9.1%, with no difference(P=0.171). Although, there was a significant difference of ED 9.7%/C 15.1% after TG(P=0.015). The rate of skeletal muscle loss at 1 year after surgery was ED 8.0%/C 10.1%(P=0.357)overall;after TG;ED 12.5%/C 17.5%(P=0.196)and after DG; ED 5.6%/C 6.2%(P=0.770), all without significant difference. Conclusion:An oral elemental nutritional supplements early after gastrectomy significantly reduced short-term postoperative weight loss, and in TG, also significantly reduced weight loss at 1 year postoperatively. No significant difference in skeletal muscle loss was detected.
- Open Access
- 22 July 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (29) , e29532
Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer
Although the antitumor effects of antihypertensive drugs for patients with advanced pancreatic cancer (APC) have been investigated, their efficacy remains unclear. Previous studies suggest that hypertensive (HT) patients with APC are significantly older than non-HT patients with APC, and that other major baseline differences in patient characteristics which may affect prognosis exist between HT and non-HT patients. It is also possible that antihypertensive drugs lack antitumor activity. Therefore, we herein retrospectively investigated the baseline differences between HT and non-HT patients with APC. From January 2015 to April 2020, 56 patients with APC received nab-paclitaxel plus gemcitabine as first-line chemotherapy at Higashiosaka City Medical Center (Higashiosaka, Japan). Of these 56 patients, 30 were diagnosed with hypertension (HT group); the remaining 26 did not have hypertension (non-HT group). Differences between the two groups were compared and prognostic factors were evaluated. Patients in the HT group had significantly less sarcopenia, a significantly larger body mass index, were significantly older, and significantly more likely to have a regular doctor and primary site in the body and tail of the pancreas than those in the non-HT group. Although no significant difference was found in the treatment response, patients in the HT group were significantly more likely to move to second-line chemotherapy than those in the non-HT group. Survival curves showed that median overall survival (OS) in the HT group was significantly longer (10.5 months) than in the non-HT group (6.8 months, P = .04). Multivariate analysis did not identify the use of antihypertensive drugs as an independent prognostic factor of OS. We identified key baseline differences in the characteristics of APC patients with and without HT, suggesting that major selection bias could occur when investigating the efficacy of antihypertensive drugs in all populations. Therefore, it is possible that antihypertensive drugs lack antitumor activity. To determine the true efficacy of antihypertensive drugs for APC, HT, and non-HT patients in another population should be investigated, or a prospective, randomized, controlled trial conducted that is stratified by HT or non-HT status.
- 22 July 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (29) , e29532
Open AccessDo antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer
Although the antitumor effects of antihypertensive drugs for patients with advanced pancreatic cancer (APC) have been investigated, their efficacy remains unclear. Previous studies suggest that hypertensive (HT) patients with APC are significantly older than non-HT patients with APC, and that other major baseline differences in patient characteristics which may affect prognosis exist between HT and non-HT patients. It is also possible that antihypertensive drugs lack antitumor activity. Therefore, we herein retrospectively investigated the baseline differences between HT and non-HT patients with APC. From January 2015 to April 2020, 56 patients with APC received nab-paclitaxel plus gemcitabine as first-line chemotherapy at Higashiosaka City Medical Center (Higashiosaka, Japan). Of these 56 patients, 30 were diagnosed with hypertension (HT group); the remaining 26 did not have hypertension (non-HT group). Differences between the two groups were compared and prognostic factors were evaluated. Patients in the HT group had significantly less sarcopenia, a significantly larger body mass index, were significantly older, and significantly more likely to have a regular doctor and primary site in the body and tail of the pancreas than those in the non-HT group. Although no significant difference was found in the treatment response, patients in the HT group were significantly more likely to move to second-line chemotherapy than those in the non-HT group. Survival curves showed that median overall survival (OS) in the HT group was significantly longer (10.5 months) than in the non-HT group (6.8 months, P = .04). Multivariate analysis did not identify the use of antihypertensive drugs as an independent prognostic factor of OS. We identified key baseline differences in the characteristics of APC patients with and without HT, suggesting that major selection bias could occur when investigating the efficacy of antihypertensive drugs in all populations. Therefore, it is possible that antihypertensive drugs lack antitumor activity. To determine the true efficacy of antihypertensive drugs for APC, HT, and non-HT patients in another population should be investigated, or a prospective, randomized, controlled trial conducted that is stratified by HT or non-HT status.
- Open Access
- 1 April 2022
- Published by The Japanese Journal of Gastroenterological Surgery in The Japanese Journal of Gastroenterological Surgery
- Vol. 55 (4) , 269-275
An Adult Case of Reverse Intestinal Malrotation with Repeated Intestinal Obstruction That Was Treated with Surgery
症例は78歳の女性で,5年前から反復する十二指腸閉塞に対して15回の保存的加療歴があった.今回も腹痛,嘔吐を主訴として受診し,CTで腸管逆回転症による十二指腸の走行異常と,十二指腸空腸曲での閉塞を認め,腸閉塞の診断で緊急入院した.腸閉塞を発症する頻度が増加しており,手術加療の方針とした.術中所見から,反復する腸閉塞の原因は腸管逆回転症による腸間膜のねじれと,それに伴う十二指腸空腸曲の圧迫が原因と考えられた.十二指腸空腸曲を周囲組織から剥離し十分に授動後,十二指腸の回転異常に伴う走行異常を整復し手術を終了した.経過は良好で,術後約1年再発なく外来で経過観察中である.腸管逆回転症は腸回転異常症の1型であり,まれな先天異常である.自験例は十二指腸が逆回転,結腸が正常回転した型の腸管逆回転症であった.腸管逆回転症を背景とした繰り返す腸閉塞に対し,手術が奏効した1例を経験したので報告する.
- 1 April 2022
- Published by The Japanese Journal of Gastroenterological Surgery in The Japanese Journal of Gastroenterological Surgery
- Vol. 55 (4) , 269-275
Open AccessAn Adult Case of Reverse Intestinal Malrotation with Repeated Intestinal Obstruction That Was Treated with Surgery
症例は78歳の女性で,5年前から反復する十二指腸閉塞に対して15回の保存的加療歴があった.今回も腹痛,嘔吐を主訴として受診し,CTで腸管逆回転症による十二指腸の走行異常と,十二指腸空腸曲での閉塞を認め,腸閉塞の診断で緊急入院した.腸閉塞を発症する頻度が増加しており,手術加療の方針とした.術中所見から,反復する腸閉塞の原因は腸管逆回転症による腸間膜のねじれと,それに伴う十二指腸空腸曲の圧迫が原因と考えられた.十二指腸空腸曲を周囲組織から剥離し十分に授動後,十二指腸の回転異常に伴う走行異常を整復し手術を終了した.経過は良好で,術後約1年再発なく外来で経過観察中である.腸管逆回転症は腸回転異常症の1型であり,まれな先天異常である.自験例は十二指腸が逆回転,結腸が正常回転した型の腸管逆回転症であった.腸管逆回転症を背景とした繰り返す腸閉塞に対し,手術が奏効した1例を経験したので報告する.
- Open Access
- 1 March 2022
- Published by International College of Surgeons in International Surgery
- Vol. 106 (2) , 67-74
Preoperative Oral-Bowel Preparation Using Sodium Picosulfate and Magnesium Citrate Combination Powder for Left-Sided Colorectal Cancer: A Prospective Study
Objective: This study aimed to determine if induction of sodium picosulfate and magnesium citrate (SPMC) preparation leads to adequate surgery for left-sided colorectal cancer (CRC).Summary of Background Data: Adequate bowel cleansing is vital for safe and accurate colorectal surgery. Ingestion of laxatives for bowel cleansing may be associated with a broad spectrum of adverse effects during surgical intervention.Methods: A single-center prospective study was conducted with hospitalized patients scheduled operation for left-sided CRC. All enrolled patients were instructed to consume normal diet until before preparation. Twenty-seven patients underwent preoperative SPMC preparation.Results: The primary endpoint of this study was the 30-day postoperative morbidity rate, which was 23%, and no postoperative complication was higher than Clavien-Dindo grade 3. The primary anastomosis rate was 100%, and there was no anastomotic leakage. The colonic cleansing grades were 1 or 2 according to the bowel preparation scale for surgical assessment in 89% of the patients. The acceptability of the cleansing procedure by the patients assessed by a questionnaire was 85%, and the acceptability of the SPMC preparation by the medical staff was 93%. The surgical procedures included 18 laparoscopies, 6 robotic surgeries, and 3 laparotomies. The median operation time was 165 minutes, and the median blood loss was <50 cc. The median sodium serum concentration was significantly decreased after surgery.Conclusion: Ingestion of an SPMC preparation as a cleansing procedure was judged to be adequate for curative surgery in patients with left-sided colorectal cancer.
- 1 March 2022
- Published by International College of Surgeons in International Surgery
- Vol. 106 (2) , 67-74
Open AccessPreoperative Oral-Bowel Preparation Using Sodium Picosulfate and Magnesium Citrate Combination Powder for Left-Sided Colorectal Cancer: A Prospective Study
Objective: This study aimed to determine if induction of sodium picosulfate and magnesium citrate (SPMC) preparation leads to adequate surgery for left-sided colorectal cancer (CRC).Summary of Background Data: Adequate bowel cleansing is vital for safe and accurate colorectal surgery. Ingestion of laxatives for bowel cleansing may be associated with a broad spectrum of adverse effects during surgical intervention.Methods: A single-center prospective study was conducted with hospitalized patients scheduled operation for left-sided CRC. All enrolled patients were instructed to consume normal diet until before preparation. Twenty-seven patients underwent preoperative SPMC preparation.Results: The primary endpoint of this study was the 30-day postoperative morbidity rate, which was 23%, and no postoperative complication was higher than Clavien-Dindo grade 3. The primary anastomosis rate was 100%, and there was no anastomotic leakage. The colonic cleansing grades were 1 or 2 according to the bowel preparation scale for surgical assessment in 89% of the patients. The acceptability of the cleansing procedure by the patients assessed by a questionnaire was 85%, and the acceptability of the SPMC preparation by the medical staff was 93%. The surgical procedures included 18 laparoscopies, 6 robotic surgeries, and 3 laparotomies. The median operation time was 165 minutes, and the median blood loss was <50 cc. The median sodium serum concentration was significantly decreased after surgery.Conclusion: Ingestion of an SPMC preparation as a cleansing procedure was judged to be adequate for curative surgery in patients with left-sided colorectal cancer.
- Open Access
- 1 January 2021
- Published by Japanese College of Surgeons in Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)
- Vol. 46 (4) , 514-521
A Case of Abdominal Wall Abscess Formation Long after Penetration of a Fish Bone that was Completely Resected Using Xeroradiography
症例は80歳代女性で,腹部の皮下腫瘤を自覚し当院を受診した.来院時,皮下腫瘤部のみ発赤と疼痛・熱感を認め,圧迫で排膿を認めた.血液検査ではCRP 14.6mg/dLと炎症反応の上昇を認めた.腹部CTでは発赤部直下腹壁内に1.7cmの線状の高吸収域を認め,1年前のCTでは同様の異物を腹腔内に認め,腸管内異物が腹壁へ穿通したことによる腹壁膿瘍と診断した.全身状態は良好であり,切開排膿・抗生剤治療後に待機的に異物摘出術を行った.エコーで異物の位置を確認し,下腹部正中切開で開腹した.腹壁に大網の癒着を切離し異物を視認できたため,把持し摘出した.異物は1cmと術前の画像で認めた異物より短径であり,遺残が疑われた.周囲の腹壁と大網を含めて追加切除し,軟線撮影で標本内に7mm大の高吸収異物が含まれていることを確認した.魚骨穿通による腹壁膿瘍は稀であり,軟線撮影により遺残なく完全切除が可能であった症例を経験したので報告する.
- 1 January 2021
- Published by Japanese College of Surgeons in Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)
- Vol. 46 (4) , 514-521
Open AccessA Case of Abdominal Wall Abscess Formation Long after Penetration of a Fish Bone that was Completely Resected Using Xeroradiography
症例は80歳代女性で,腹部の皮下腫瘤を自覚し当院を受診した.来院時,皮下腫瘤部のみ発赤と疼痛・熱感を認め,圧迫で排膿を認めた.血液検査ではCRP 14.6mg/dLと炎症反応の上昇を認めた.腹部CTでは発赤部直下腹壁内に1.7cmの線状の高吸収域を認め,1年前のCTでは同様の異物を腹腔内に認め,腸管内異物が腹壁へ穿通したことによる腹壁膿瘍と診断した.全身状態は良好であり,切開排膿・抗生剤治療後に待機的に異物摘出術を行った.エコーで異物の位置を確認し,下腹部正中切開で開腹した.腹壁に大網の癒着を切離し異物を視認できたため,把持し摘出した.異物は1cmと術前の画像で認めた異物より短径であり,遺残が疑われた.周囲の腹壁と大網を含めて追加切除し,軟線撮影で標本内に7mm大の高吸収異物が含まれていることを確認した.魚骨穿通による腹壁膿瘍は稀であり,軟線撮影により遺残なく完全切除が可能であった症例を経験したので報告する.
- Open Access
- 1 January 2020
- Published by Japanese College of Surgeons in Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)
- Vol. 45 (6) , 830-835
A Case of a Foreign Body, a Melon, in the Rectum Removed Using Two Myoma Borers
症例は68歳,男性.自慰目的で肛門から瓜を挿入し,排出困難となり当院を受診した.腹部単純CTで16×7cm大の瓜を直腸RS付近に認め,腸管穿孔所見は認めなかった.摘出の際に腸管損傷の可能性を考え,全身麻酔下での摘出を試みた.全身麻酔下,砕石位で手術を開始した.肛門括約筋の弛緩は得られたが肛門内に異物は確認できず,下腹部圧排で瓜の頂部をわずかに確認できた.ミュゾー鉗子で把持を試みるも困難であり,子宮筋腫用のミオームボーラーを瓜に挿入し,下腹部の圧排と牽引で摘出を試みた.しかし,瓜は脆弱でミオームボーラー挿入部が砕けるため,別角度からもう1本挿入することで力を分散し脆弱性を補うことで腹部圧迫を併用し摘出に成功した.直腸異物は多種多様の異物が報告されており,摘出方法の工夫が必要である.今回直腸異物(瓜)に対して,異物の大きさと摘出器具の特徴を術前に綿密に確認することで安全に摘出しえた症例を経験した.
- 1 January 2020
- Published by Japanese College of Surgeons in Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)
- Vol. 45 (6) , 830-835
Open AccessA Case of a Foreign Body, a Melon, in the Rectum Removed Using Two Myoma Borers
症例は68歳,男性.自慰目的で肛門から瓜を挿入し,排出困難となり当院を受診した.腹部単純CTで16×7cm大の瓜を直腸RS付近に認め,腸管穿孔所見は認めなかった.摘出の際に腸管損傷の可能性を考え,全身麻酔下での摘出を試みた.全身麻酔下,砕石位で手術を開始した.肛門括約筋の弛緩は得られたが肛門内に異物は確認できず,下腹部圧排で瓜の頂部をわずかに確認できた.ミュゾー鉗子で把持を試みるも困難であり,子宮筋腫用のミオームボーラーを瓜に挿入し,下腹部の圧排と牽引で摘出を試みた.しかし,瓜は脆弱でミオームボーラー挿入部が砕けるため,別角度からもう1本挿入することで力を分散し脆弱性を補うことで腹部圧迫を併用し摘出に成功した.直腸異物は多種多様の異物が報告されており,摘出方法の工夫が必要である.今回直腸異物(瓜)に対して,異物の大きさと摘出器具の特徴を術前に綿密に確認することで安全に摘出しえた症例を経験した.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e15546
A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: OGSG1203 (HERBIS-5).
E15546 Background: Irinotecan is a key drug in second- or further-line chemotherapy for patients with advanced gastric cancer. Continuous administration of trastuzumab beyond first progression is expected to contribute to the benefit of chemotherapy for HER2-positive gastric cancer. We assessed the efficacy and safety of combination chemotherapy with trastuzumab and irinotecan in Japanese patients with advanced HER2-positive chemo-refractory gastric cancer. Methods: Intravenous infusion of irinotecan every 2 weeks at a dose of 150 mg/m2; intravenous infusion of trastuzumab at a dose of 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks. Administration of irinotecan and trastuzumab were repeated in independent schedules. The primary endpoint was disease control rate (DCR). The secondary endpoints were adverse events (AEs), response rate (RR), time-to-treatment failure (TTF), progression-free survival (PFS) , overall survival (OS), and RR stratified by prior trastuzumab use. This study was conducted by the Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG). Results: From October 2012 to Augst 2014, 30 patients were enrolled and one patient withdrew before study treatment. Accordingly, 29 patients were assessable for efficacy and safety. The DCR was 65.5% [95% C.I. 45.7 - 82.1%], and the RR was 20.7% [95% C.I. 8.0 - 39.7%]. The median PFS and OS were 3.7 and 7.5 months, respectively. The major grade 3/4 AEs were neutropenia (24%); anemia (24%); leucopenia (21%); anorexia (11%); fatigue (14%); hypoalbuminemia (24%); and hypokalemia (14%). One death (NOS) was considered to be related to the study. Treatment courses and relative dose intensity of each drugs were 6times (range: 1-23), 91.1 % (52.9-101.4) in irinotecan, and 5 times (1-17), 100.0% (61.3-102.9) in trastuzumab, respectively. Conclusions: The results of combination trastuzumab with irinotecan showed feasible and promising efficacy against advanced HER2-positive chemo-refractory gastric cancer. These findings indicated that trastuzumab continuation use might be beneficial. Clinical trial information: 000008626.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e15546
A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: OGSG1203 (HERBIS-5).
E15546 Background: Irinotecan is a key drug in second- or further-line chemotherapy for patients with advanced gastric cancer. Continuous administration of trastuzumab beyond first progression is expected to contribute to the benefit of chemotherapy for HER2-positive gastric cancer. We assessed the efficacy and safety of combination chemotherapy with trastuzumab and irinotecan in Japanese patients with advanced HER2-positive chemo-refractory gastric cancer. Methods: Intravenous infusion of irinotecan every 2 weeks at a dose of 150 mg/m2; intravenous infusion of trastuzumab at a dose of 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks. Administration of irinotecan and trastuzumab were repeated in independent schedules. The primary endpoint was disease control rate (DCR). The secondary endpoints were adverse events (AEs), response rate (RR), time-to-treatment failure (TTF), progression-free survival (PFS) , overall survival (OS), and RR stratified by prior trastuzumab use. This study was conducted by the Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG). Results: From October 2012 to Augst 2014, 30 patients were enrolled and one patient withdrew before study treatment. Accordingly, 29 patients were assessable for efficacy and safety. The DCR was 65.5% [95% C.I. 45.7 - 82.1%], and the RR was 20.7% [95% C.I. 8.0 - 39.7%]. The median PFS and OS were 3.7 and 7.5 months, respectively. The major grade 3/4 AEs were neutropenia (24%); anemia (24%); leucopenia (21%); anorexia (11%); fatigue (14%); hypoalbuminemia (24%); and hypokalemia (14%). One death (NOS) was considered to be related to the study. Treatment courses and relative dose intensity of each drugs were 6times (range: 1-23), 91.1 % (52.9-101.4) in irinotecan, and 5 times (1-17), 100.0% (61.3-102.9) in trastuzumab, respectively. Conclusions: The results of combination trastuzumab with irinotecan showed feasible and promising efficacy against advanced HER2-positive chemo-refractory gastric cancer. These findings indicated that trastuzumab continuation use might be beneficial. Clinical trial information: 000008626.